Tacquell, Yartemlea, and Xervyteg failed to secure positive CHMP recommendations after EMA identified major concerns with efficacy, safety, and data interpretability.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/ema-turns-down-3-therapies-across-oncology-transplantation-2026a1000lzz?src=rss
Author :
Publish date : 2026-06-29 12:16:00
Copyright for syndicated content belongs to the linked Source.
